{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:12Z","timestamp":1783617372489,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40121-026-01370-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:02:23Z","timestamp":1780887743000},"page":"2017-2025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Podcast: Immune Persistence After Primary Vaccination with MenQuadfi"],"prefix":"10.1007","volume":"15","author":[{"given":"Mika","family":"R\u00e4met","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"1370_CR1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000328","volume":"151","author":"CP de Santayana","year":"2023","unstructured":"de Santayana CP, Htar MTT, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review. Epidemiol Infect. 2023;151:e57.","journal-title":"Epidemiol Infect"},{"key":"1370_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","volume":"799","author":"NG Rouphael","year":"2012","unstructured":"Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1\u201320.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1370_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","volume":"23","author":"R Borrow","year":"2024","unstructured":"Borrow R, Findlow J. The important lessons lurking in the history of meningococcal epidemiology. Expert Rev Vaccines. 2024;23(1):445\u201362.","journal-title":"Expert Rev Vaccines"},{"key":"1370_CR4","unstructured":"CDC Yellow Book. Meningococcal disease. In: CDC Yellow Book: Health Information for International Travel. 2026 ed. Centers for Disease Control and Prevention; 2025. Available from: https:\/\/www.cdc.gov\/yellow-book\/hcp\/travel-associated-infections-diseases\/meningococcal-disease.html. Accessed March 2026."},{"key":"1370_CR5","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease. In: Annual Epidemiological Report for 2022. Stockholm: ECDC; 2024. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/invasive-meningococcal-disease-annual-epidemiological-report-2022. Accessed March 2026."},{"issue":"1","key":"1370_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11010178","volume":"11","author":"A Conti","year":"2023","unstructured":"Conti A, Broglia G, Sacchi C, Risi F, Barone-Adesi F, Panella M. Efficacy and safety of quadrivalent conjugate meningococcal vaccines: a systematic review and meta-analysis. Vaccines. 2023;11(1):178.","journal-title":"Vaccines"},{"issue":"10","key":"1370_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101521","volume":"8","author":"M Pizza","year":"2020","unstructured":"Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8(10):1521.","journal-title":"Microorganisms"},{"issue":"Suppl 2","key":"1370_CR8","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1086\/648964","volume":"50","author":"G Poland","year":"2010","unstructured":"Poland G. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis. 2010;50(Suppl 2):S45\u201353.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1370_CR9","doi-asserted-by":"publisher","first-page":"24990","DOI":"10.1038\/s41598-025-08112-0","volume":"15","author":"L Coudeville","year":"2025","unstructured":"Coudeville L, Bertrand-Gerentes I, Zocchetti C, et al. Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines. Sci Rep. 2025;15(1):24990.","journal-title":"Sci Rep"},{"issue":"1","key":"1370_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2516949","volume":"21","author":"EC Dinleyici","year":"2025","unstructured":"Dinleyici EC, Ciftci E, Somer A, Yilmaz D, Tezer H. A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi\u00ae (MENACWY-TT). Hum Vaccin Immunother. 2025;21(1):2516949.","journal-title":"Hum Vaccin Immunother"},{"key":"1370_CR11","unstructured":"Centers for Disease Control and Prevention (CDC). Meningococcal vaccine recommendations. CDC.gov. Published July 1, 2025. Available from: https:\/\/www.cdc.gov\/meningococcal\/hcp\/vaccine-recommendations\/index.html. Accessed March 2026."},{"key":"1370_CR12","unstructured":"Pfizer Inc. CDC recommendations for TRUMENBA\u00ae (Meningococcal Group B Vaccine). PfizerPro.com. Available from: https:\/\/trumenba.pfizerpro.com\/about\/cdc-recommendations. Accessed March 2026."},{"key":"1370_CR13","unstructured":"American Society for Meningitis Prevention. Meningitis vaccine tracker. MeningitisPrevention.org. Last updated September 2025. Available from: https:\/\/meningitisprevention.org\/meningitis-vaccine-tracker. Accessed March 2026."},{"key":"1370_CR14","doi-asserted-by":"publisher","first-page":"1000657","DOI":"10.3389\/fped.2022.1000657","volume":"10","author":"G Pinto Cardoso","year":"2022","unstructured":"Pinto Cardoso G, Lagr\u00e9e-Chastan M, Caseris M, et al. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries. Front Pediatr. 2022;10:1000657.","journal-title":"Front Pediatr"},{"key":"1370_CR15","unstructured":"Meningitis Research Foundation. Vaccines \u2013 Meningitis Progress Tracker. Tracker.Meningitis.org. Published July 2025. Available from: https:\/\/tracker.meningitis.org\/vaccines\/. Accessed March 2026."},{"issue":"8","key":"1370_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.4161\/hv.20473","volume":"8","author":"KS Erlich","year":"2012","unstructured":"Erlich KS, Congeni BL. Importance of circulating antibodies in protection against meningococcal disease. Hum Vaccin Immunother. 2012;8(8):1029\u201335.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1370_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson CA, Jacqumein J, Selmani A, Galarza K, Oster P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged \u226559 years: a phase III randomized study. Hum Vaccin Immunother. 2023;19(1):2160600.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"1370_CR18","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s40121-023-00864-4","volume":"12","author":"D Neveu","year":"2023","unstructured":"Neveu D, Moore TM, Zambrano B, et al. Structured benefit-risk assessment of a new quadrivalent meningococcal conjugate vaccine (MenACYW-TT) in individuals ages 12 months and older. Infect Dis Ther. 2023;12(10):2367\u201386.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1370_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1902701","volume":"18","author":"FM Piazza","year":"2022","unstructured":"Piazza FM, Virta M, Paassilta M, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a phase III, open-label, multi-center study. Hum Vaccin Immunother. 2022;18(1):1\u201310.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1370_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40121-025-01121-6","volume":"14","author":"F Martin\u00f3n-Torres","year":"2025","unstructured":"Martin\u00f3n-Torres F, Simko R, Ebert R, et al. Five-year immune persistence of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) and immunogenicity and safety of a booster dose in children. Infect Dis Ther. 2025;14(5):991\u20131010.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"1370_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41390-023-02478-5","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano B, Peterson J, Deseda C, et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023;94(3):1035\u201343.","journal-title":"Pediatr Res"},{"issue":"6","key":"1370_CR22","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/s41390-024-03760-w","volume":"97","author":"J Peterson","year":"2025","unstructured":"Peterson J, Galarza K, Bchir S, Zocchetti C, Bertrand-Gerentes I, Zambrano B. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in children aged 10\u201312 years: phase III randomized trial complementary analysis of immune persistence 3\u20136 years after priming. Pediatr Res. 2025;97(6):1800\u20132.","journal-title":"Pediatr Res"},{"issue":"1","key":"1370_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2426868","volume":"20","author":"CA Robertson","year":"2024","unstructured":"Robertson CA, Jacqumein J, Selmani A, Galarza K, Oster O. Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at \u226556 years of age. Hum Vaccin Immunother. 2024;20(1):2426868.","journal-title":"Hum Vaccin Immunother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01370-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:06:16Z","timestamp":1783616776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01370-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01370-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mika R\u00e4met declares that his institution was sponsored by Sanofi to perform the MEQ73 study. Finnish Vaccine Research Ltd. (formerly Tampere University Vaccine Research Center) carries out clinical vaccine trials sponsored by all major vaccine manufacturers including Sanofi. Mike Simon declares that he is a clinical investigator for Sanofi, GlaxoSmithKline, Moderna, AbbVie and Novan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}